Business
Novocure Secures CE Mark for New Array
New arrays are lighter, thinner and more flexible than current commercial arrays and have the potential to optimize Tumor Treating Fields dose ROOT,
About this update from Novocure Limited
[{"type":"text","content":"\nNew arrays are lighter, thinner and more flexible than current commercial arrays and have the potential to optimize Tumor Treating Fields dose\n\n ROOT, Switzerland--(BUSINESS WIRE)--\nNovocure (NASDAQ: NVCR) today announced receipt of CE Mark for its new polymer-based transducer array, called the flex array, designed for more efficient Tumor Treating Fields delivery and greater comfort for patients with glioblastoma. The new arrays are more than 50% thinner and more than 30% lighter compared to current commercial arrays.\n\n“Novocure is committed to improving the patient experience and clinical outcomes through innovation, and the new arrays represent a meaningful milestone reached in our product development journey,” said Mukund Paravasthu, Novocure’s Senior Vice President, Product Development. “Through product innovation, our goal is to deliver higher intensity TTFields to targeted regions without adding toxicity. We believe the new arrays have the potential to meaningfully improve both patient comfort and efficacy of our therapy.”\n\nWith CE Mark for the new arrays, the company will begin a limited market release in Europe. Initial patient experience will inform regulatory filings and launch plans in additional active markets.\n\nAbout Tumor Treating Fields Therapy\nTumor Treating Fields (TTFields) are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. TTFields do not significantly affect healthy cells because they have different properties (including division rate, morphology, and electrical properties) than cancer cells. The multiple, distinct mechanisms of TTFields therapy work together to selectively target and kill cancer cells. Due to its multimechanistic actions, TTFields therapy can be added to cancer treatment modalities in approved indications and demonstrates enhanced effects across solid tumor types when used with chemotherapy, radiotherapy, immune checkpoint inhibition, or PARP inhibition in preclinical models. TTFields therapy provides clinical versatility that has the potential to help address treatment challenges across a range of solid tumors. To learn more about Tumor Treating Fields therapy and its multifaceted effect on cancer cells, visit tumortreatingfields.com.\n\nAbout Novocure\nNovocure is a global oncology company working to extend survival in some of the ...